Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nolan-Kenney Rachel C, Liu Mengling, Akhand Omar, Calabresi Peter A, Paul Friedemann, Petzold Axel, Balk Lisanne, Brandt Alexander U, Martínez-Lapiscina Elena H, Saidha Shiv, Villoslada Pablo, Al-Hassan Abdullah Abu, Behbehani Raed, Frohman Elliot M, Frohman Teresa, Havla Joachim, Hemmer Bernhard, Jiang Hong, Knier Benjamin, Korn Thomas, Leocani Letizia, Papadopoulou Athina, Pisa Marco, Zimmermann Hanna, Galetta Steven L, Balcer Laura J, International Multiple Sclerosis Visual System Consortium
Аннотация
METHODS: In this multicenter international study at 11 sites, optical coherence tomography was measured for patients and healthy controls as part of the International Multiple Sclerosis Visual System Consortium. High- and low-contrast acuity were also collected in a subset of participants. Presence of an optic nerve lesion for this study was defined as history of acute unilateral optic neuritis.
RESULTS: Among patients (n = 1,530), receiver operating characteristic curve analysis demonstrated an optimal peripapillary retinal nerve fiber layer intereye difference threshold of 5μm and ganglion cell + inner plexiform layer threshold of 4μm for identifying unilateral optic neuritis (n = 477). Greater intereye differences in acuities were associated with greater intereye retinal layer thickness differences (p ≤ 0.001).
INTERPRETATION: Intereye differences of 5μm for retinal nerve fiber layer and 4μm for macular ganglion cell + inner plexiform layer are robust thresholds for identifying unilateral optic nerve lesions. These thresholds may be useful in establishing the presence of asymptomatic and symptomatic optic nerve lesions in multiple sclerosis and could be useful in a new version of the diagnostic criteria. Our findings lend further validation for utilizing the visual system in a multiple sclerosis clinical trial setting. Ann Neurol 2019;85:618-629.